AI assistant
HAEMONETICS CORP — Director's Dealing 2024
May 29, 2024
31565_dirs_2024-05-29_8d317378-4dc9-4b1a-adf4-97a164043a02.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-28
Reporting Person: Lingamneni Anila (EVP, Chief Technology Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-28 | Common Stock | A | 14140 | — | Acquired | 28825 | Direct |
| 2024-05-28 | Common Stock | F | 5279 | $95.73 | Disposed | 23546 | Direct |
Footnotes
F1: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.
F2: This number includes unvested restricted stock units ("RSUs") previously reported.
F3: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.